Back to Search
Start Over
Hydrogen Sulfide: Recent Progression and Perspectives for the Treatment of Diabetic Nephropathy.
Hydrogen Sulfide: Recent Progression and Perspectives for the Treatment of Diabetic Nephropathy.
- Source :
-
Molecules (Basel, Switzerland) [Molecules] 2019 Aug 06; Vol. 24 (15). Date of Electronic Publication: 2019 Aug 06. - Publication Year :
- 2019
-
Abstract
- Diabetic kidney disease develops in approximately 40% of diabetic patients and is a major cause of chronic kidney diseases (CKD) and end stage kidney disease (ESKD) worldwide. Hydrogen sulfide (H <subscript>2</subscript> S), the third gasotransmitter after nitric oxide (NO) and carbon monoxide (CO), is synthesized in nearly all organs, including the kidney. Though studies on H <subscript>2</subscript> S regulation of renal physiology and pathophysiology are still in its infancy, emerging evidence shows that H <subscript>2</subscript> S production by renal cells is reduced under disease states and H <subscript>2</subscript> S donors ameliorate kidney injury. Specifically, aberrant H <subscript>2</subscript> S level is implicated in various renal pathological conditions including diabetic nephropathy. This review presents the roles of H <subscript>2</subscript> S in diabetic renal disease and the underlying mechanisms for the protective effects of H <subscript>2</subscript> S against diabetic renal damage. H <subscript>2</subscript> S may serve as fundamental strategies to treat diabetic kidney disease. These H <subscript>2</subscript> S treatment modalities include precursors for H <subscript>2</subscript> S synthesis, H <subscript>2</subscript> S donors, and natural plant-derived compounds. Despite accumulating evidence from experimental studies suggests the potential role of the H <subscript>2</subscript> S signaling pathway in the treatment of diabetic nephropathy, these results need further clinical translation. Expanding understanding of H <subscript>2</subscript> S in the kidney may be vital to translate H <subscript>2</subscript> S to be a novel therapy for diabetic renal disease.<br />Competing Interests: The author declares no conflict of interest.
- Subjects :
- Animals
Diabetic Nephropathies drug therapy
Diabetic Nephropathies etiology
Diabetic Nephropathies metabolism
Diabetic Nephropathies pathology
Drug Evaluation, Preclinical
Fibrosis
Humans
Hydrogen Sulfide chemistry
Hydrogen Sulfide pharmacology
Hydrogen Sulfide therapeutic use
Kidney Glomerulus drug effects
Kidney Glomerulus metabolism
Kidney Glomerulus pathology
Metabolic Networks and Pathways drug effects
Nitric Oxide metabolism
Oxidative Stress drug effects
Oxygen metabolism
Podocytes metabolism
Podocytes pathology
Renin-Angiotensin System
Hydrogen Sulfide metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1420-3049
- Volume :
- 24
- Issue :
- 15
- Database :
- MEDLINE
- Journal :
- Molecules (Basel, Switzerland)
- Publication Type :
- Academic Journal
- Accession number :
- 31390847
- Full Text :
- https://doi.org/10.3390/molecules24152857